Testing effectiveness (Phase 2)Not Yet RecruitingNCT07788365
What this trial is testing
Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas: A Phase II Proof-of-concept Study
Who this might be right for
Diagnosis of Neuro-endocrine Carcinoma of the Gynecological Tract
University Hospital, Strasbourg, France 20